H.C. Wainwright Upgrades Context Therapeutics (CNTX) to Buy, 'CTIM-76 could be more effective than competitors'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to H.C. Wainwright Upgrades Context Therapeutics (CNTX) to Buy, 'CTIM-76 could be more effective than competitors'

Context Therapeutics (CNTX) Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

October 31, 2023 9:01 AM EDT

Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Companys preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.

Findings from Contexts research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors. Notably:

CTIM-76 was shown to have high potency and target selectivity in both binding and cytotoxicity assays.In in vivo... More